arrow
X

Xiaoling Chen

department of pathology
H指数:31
被引数:2,866

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epilepsy-associated SCN2A-L1342P mutation drives network hyperexcitability and widespread transcriptomic changes in human cortical organoids

癫痫相关SCN2A-L1342P突变驱动人皮质类器官中的网络高兴奋性和广泛的转录组变化

2026-07-310
OAAI
Single-nucleus transcriptomics reveals disrupted pathways in the prefrontal cortex of Scn2a-deficient mice

单核转录组学揭示Scn2a缺陷小鼠前额叶皮层中的紊乱通路

2026-07-310
OA
Human microglia in brain assembloids display region-specific diversity and respond to hyperexcitable neurons carrying SCN2A mutation

人脑类脑体中的微胶质细胞表现出区域特异性多样性,并对携带SCN2A突变的过度兴奋神经元产生反应

2026-02-180
OA
Global emergence and transmission dynamics of carbapenemase-producing Citrobacter freundii sequence type 22 high-risk international clone: a retrospective, genomic, epidemiological study

全球产碳青霉烯酶的弗劳地柠檬酸杆菌序列型22高危国际克隆的出现与传播动态:一项回顾性、基因组学及流行病学研究

2025-07-160
OAAI
First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

FAZ053的首次人体研究,FAZ053是一种抗程序性死亡配体1(anti-PD-L1)单克隆抗体,单独使用及与spartalizumab(抗PD-1)联用,用于治疗晚期恶性肿瘤患者

2025-06-010
PRE
Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: An open-label, non-comparative, randomised, phase II trial

Balstilimab (bal) 单药或联合 zalifrelimab (zal) 治疗宫颈癌:一项开放标签、非比较性、随机化、II 期临床试验

2024-12-010
PRE